Established in January 2018, BRSM is China's first preclinical CRO specializing in the evaluation of respiratory disease therapeutics, with a particular focus on inhaled formulations. Our company originated from the Zhejiang University Respiratory Drug Research Laboratory, formerly affiliated with the China National Medical Products Administration (NMPA). Our expert team includes a national respiratory pharmacology evaluation specialist for new drug applications, the former BD head of WuXi AppTec North America, a leading figure in China’s inhaled drug R&D, and overseas-returned PhDs from prestigious universities.

Our team pioneered preclinical biological evaluation for inhaled drugs in China, with deep expertise in respiratory pharmacology and immunopharmacology. We possess extensive experience in preclinical assessment of respiratory therapeutics, anti-inflammatory/immunomodulatory drugs, and inhaled formulations. We are a national leader in screening and developing drugs for respiratory diseases, anti-inflammatory/immunomodulatory agents, as well as novel and improved drugs adaptable for inhalation delivery.

Currently, we have a R&D team of 30+ members, including researchers, PhDs, master's graduates, and bachelor's specialists, supported by specialized instruments valued at approximately ¥20 million.

Located in Tianhe Hi-Tech Park, Binjiang District, Hangzhou, our 2,000-square-meter facility includes 1,000 sqm of functional labs and a 500-sqm SPF-grade animal room. We offer comprehensive preclinical research platforms covering:

· Experimental animal studies

· Pharmacodynamic evaluation

· Non-clinical safety assessment

· Pharmacokinetic studies

· Pathophysiological evaluation

Equipped with full-scale preclinical biological evaluation instruments, we have established mature and stable disease models for respiratory and anti-inflammatory/immunomodulatory research, including cell models, organoid models, and China’s first non-human primate asthma model, backed by multiple proprietary technologies.

We have assisted pharmaceutical companies in completing preclinical evaluations for chemical drugs, biologics, traditional Chinese medicines, and natural products, with several approvals for clinical trials or production. Moving forward, we aim to build an integrated drug R&D pipeline—from target identification, drug synthesis, formulation development, and preclinical evaluation to clinical trial collaboration—enabling seamless end-to-end support.

Our full-spectrum CRO services include:

· Drug screening

· Efficacy evaluation

· Toxicity assessment

· Formulation R&D

· Preclinical evaluation

· Regulatory submission support